Avalon GloboCare (CHGA) & Its Peers Financial Comparison

Avalon GloboCare (NASDAQ:CHGA) is one of 953 publicly-traded companies in the “Software” industry, but how does it contrast to its competitors? We will compare Avalon GloboCare to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Risk and Volatility

Avalon GloboCare has a beta of -0.15, meaning that its share price is 115% less volatile than the S&P 500. Comparatively, Avalon GloboCare’s competitors have a beta of 1.34, meaning that their average share price is 34% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Avalon GloboCare and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1	0	0	0	1.00
Avalon GloboCare Competitors	5738	21496	44826	1493	2.57

As a group, “Software” companies have a potential upside of 28.72%. Given Avalon GloboCare’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Avalon GloboCare has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Avalon GloboCare and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Avalon GloboCare	N/A	-$18.26 million	-0.06
Avalon GloboCare Competitors	$1.91 billion	$386.80 million	106.86

Avalon GloboCare’s competitors have higher revenue and earnings than Avalon GloboCare. Avalon GloboCare is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 41.8% of shares of all “Software” companies are owned by institutional investors. 16.8% of Avalon GloboCare shares are owned by insiders. Comparatively, 19.9% of shares of all “Software” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Avalon GloboCare and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-53.69%
Avalon GloboCare Competitors	-612.41%	21.13%	-8.86%

Summary

Avalon GloboCare competitors beat Avalon GloboCare on 12 of the 13 factors compared.

Avalon GloboCare Company Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.